Strategic Initiative

Slingshot members are tracking this corporate initiative:

Atara Bio (ATRA) Announces Clinical Trial Collaboration with Merck (MRK) Evaluating ATA129 + Keytruda in Patients with Platinum-Resistant or Recurrent EBV-Associated Nasopharyngeal Carcinoma (NPC)

Source Link:: http://investors.atarabio.com/releasedetail.cfm?ReleaseID=1022290

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies

Importance

High

Medium

Low

Impact on Stocks

ATRA

100%

MRK

100%

SIGN ME UP
I want to vote! LOG ME IN
Now!

Slingshot Insights Explained

JOIN FOR FREE TODAY

Strategic Initiative Date

Announcement Date:

Apr 21, 2017

Projected Implementation:

Q2, 2017

Relevance Tracked Until:

Q2, 2019

Related Projects

Don’t see a project related to the strategic initiative you care about?

Related Keywords Ata129, Keytruda, Platinum-resistant, Ebv-associated, Nasopharyngeal Carcinoma, Npc